Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7339511 | 1.00 | PKM (0.60) | PKMSMN1; SMN2MEN1KMT2AHSD17B10 | |
| SCHEMBL16580220 | 0.85 | SMN1; SMN2 (0.66) | PKMSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL21142539 | 0.85 | SMN1; SMN2 (0.66) | PKMSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL15429761 | 0.83 | SMN1; SMN2 (0.64) | PKMSMN1; SMN2HTTCTSSNPC1 | |
| SCHEMBL6445944 | 0.83 | SMN1; SMN2 (0.64) | PKMSMN1; SMN2HTTCTSSNPC1 | |
| SCHEMBL5839241 | 0.83 | SMN1; SMN2 (0.64) | PKMSMN1; SMN2HTTCTSSNPC1 | |
| SCHEMBL18870809 | 0.82 | SMN1; SMN2 (0.62) | PKMSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL7308065 | 0.82 | MEN1 (0.52) | PKMSMN1; SMN2MEN1KMT2AHSD17B10 | |
| SCHEMBL7279963 | 0.82 | MEN1 (0.52) | PKMSMN1; SMN2MEN1KMT2AHSD17B10 | |
| SCHEMBL31618840 | 0.81 | MEN1 (0.51) | PKMSMN1; SMN2MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128434-A1 | Alpha-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | ZIMMERMAN MARY P (US) | 2002-09-12 | — | — | US | disclosed |
| US-6147188-A | IRREVERSIBLE CATHEPSIN OR CALPAIN INHIBITORS | PROTOTEK, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0997459-A1 | Intermediates for preparing retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0863883-A4 | — | — | 1998-09-16 | — | — | EP | disclosed |
| EP-0863883-A1 | ALPHA-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS | PROTOTEK, INC., (US) | 1998-09-16 | — | — | EP | disclosed |
| US-5714484-A | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | PROTOTEK, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5648497-A | Retroviral protease inhibiting compounds | ABBOTT LABORAOTRIES (US) | 1997-07-15 | — | — | US | disclosed |
| US-5616714-A | PYRIDYL, THIAZOLYL-SUBSTITUTED AMINO ACID DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-04-01 | — | — | US | disclosed |
| US-5597926-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1997-01-28 | — | — | US | disclosed |
| WO-1996040647-A1 | α-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS | PROTOTEK, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5554783-A | (2R, 3R, 4S, 5S)-3-ACETOXY-2,5-BIS/BENZYLOXYCARBONYLAMINO/ -4-BROMO-1,5-DIPHENYLHEXANE | ABBOTT LABORATORIES (US) | 1996-09-10 | — | — | US | disclosed |
| US-5541334-A | TREATING HIV | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | disclosed |
| US-5354866-A | Treating HIV infections | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0486948-A2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128434-A1 | Alpha-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | CPN1, CTRL, SERPINB1 | PKM 1856/4885SMN1; SMN2 4732/4885MEN1 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.